Case Report

CT, MRI, and FDG-PET imaging findings of low-grade extrauterine endometrial stromal sarcoma arising from the mesentery: A case report

Satoshi Suzuki, MD, Ryo Kurokawa, MD, PhD, Tetsushi Tsuruga, MD, PhD, Mayuyo Mori-Uchino, MD, PhD, Haruka Nishida, MD, PhD, Tomoyasu Kato, MD, PhD, Hiroyuki Abe, MD, PhD, Tetsuo Ushiku, MD, PhD, Shiori Amemiya, MD, PhD, Akira Katayama, MD, Osamu Abe, MD, PhD

a Department of Radiology, Graduate School of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8655, Japan
b Department of Obstetrics and Gynecology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan
c Department of Gynecology, National Cancer Center Hospital, Tokyo, Japan
d Department of Pathology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan

A R T I C L E   I N F O

Article history:
Received 15 June 2021
Revised 20 June 2021
Accepted 21 June 2021

Keywords:
Extrauterine endometrial stromal sarcoma
Mesentery
JAZF1
Computed tomography
Magnetic resonance imaging
Fluorodeoxyglucose–positron emission tomography

A B S T R A C T

Endometrial stromal sarcoma is a rare uterine mesenchymal neoplasm, and extrauterine endometrial stromal sarcoma is even rarer, with a limited number of case reports. In the present report, we present a case of low-grade extrauterine endometrial stromal sarcoma originating from the mesentery in a 49-year-old woman, without endometrial stromal sarcoma in the uterus or evidence of endometriosis. The tumor was diagnosed using recombination of the JAZF1 gene by fluorescence in situ hybridization. Computed tomography, magnetic resonance imaging, and 18F-fluorodeoxyglucose positron emission tomography/computed tomography showed a 13 cm, primarily polycystic, mass containing a contrast-enhancing solid component with restricted diffusion and mild 18F-fluorodeoxyglucose uptake. A large cystic component may be a characteristic feature of extrauterine endometrial stromal sarcoma, given the low pressure from the surrounding tissues.

© 2021 The Authors. Published by Elsevier Inc. on behalf of University of Washington. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)
Introduction

Endometrial stromal sarcoma (ESS) is a rare uterine mesenchymal neoplasm, accounting for < 10% of uterine sarcomas and 0.2% of all primary malignant tumors of the uterus [1]. In the 2020 World Health Organization (WHO) “Classification of Tumours of Female Reproductive Organs,” endometrial stromal tumors and related ovarian eruptions were classified into four categories: benign endometrial stromal nodules, low-grade ESS (LGESS), high-grade ESS (HGE), and undifferentiated uterine sarcoma [2]. Exteruterine ESS (ESS) is an even rarer entity, thought to originate from foci of endometriosis [3]. Most reports on ESS involve cases of LGESS, few cases of HGE [4,5], and no cases of benign endometrial stromal nodules or undifferentiated uterine sarcoma, which is in-line with the frequency of each category in uterine ESS. Here, we present a case of low-grade ESS in the mesentery with no evidence of primary uterine ESS or endometriosis.

Case report

A 49-year-old woman with increasing lower abdominal pain was referred to our institution 4 months after undergoing a medical check-up with ovarian enlargement. Ultrasonography detected a solid polycystic mass measuring 12 × 12 cm. She had no medical history other than depression, and no family history of malignancies, except for her father, who had prostate cancer. Laboratory analysis was not significant except for a slight increase in CA-125 of 42 U/mL (normal range, 0-35 U/mL).

Contrast-enhanced computed tomography (CT) revealed a 13 cm solid and cystic mass with contrast enhancement (Fig. 1). The dorsal edge of the mass was ill-defined, and internal walls were found within the mass. The mesenteric vein, which was suspected to be the drainage vein, was located at the periphery of the mass (Fig. 1B). On magnetic resonance imaging (MRI), the solid part of the tumor showed heterogeneous intensity on T2-weighted imaging (T2WI) and T1-weighted imaging (T1WI) with restricted diffusion (Fig. 2). No abnormality was suspected in the uterus, other than typical leiomyomas, and both ovaries were normal. 18F-fluorodeoxyglucose positron emission tomography/CT (FDG-PET/CT) was also performed, on which FDG accumulated in the solid part of the tumor with a maximum standardized uptake value (SUVmax) of 4.5 and 5.9 at 1 and 2 h after isotope injection, respectively (Fig. 3). No metastasis was observed.

Malignancies, including gastrointestinal stromal tumors, were considered for the differential diagnosis, and laparotomy was performed. Direct visual inspection during surgery revealed that the uterus and ovaries were intact, and the mass was confirmed to arise from the mesentery (Fig. 4), after which it was removed. No metastasis or dissemination was observed.

Macroscopically, the tumor was polycystic with a soft, yellow-white solid component. Histologically, diffuse proliferation of cells with ovoid- to spindle-like nuclei and clear cytoplasm was observed (Fig. 5). Cell density was high in a few regions of hemorrhage, edema, and necrosis. The tumor was covered with a fibrous capsule, and the margins were negative. Several foci of venous invasion were observed. Ki-67 was positive in approximately 20% of cells. Immunohistochemically, proliferating cells were positive for cluster of differentiation 10 (CD10) and estrogen receptor (ER). The recombination of the JAZF1 gene was identified by fluorescence in situ hybridization (FISH), and the tumor was diagnosed as low-grade ESS. No PHF1 gene recombinations were observed. Because uterine involvement was highly suspected, hysterectomy and bilateral salpingo-oophorectomy were performed; however, no malignancy or endometriosis was observed. After discharge, the patient was regularly attended follow-up visits.

Discussion

We have reported herein a case of low-grade ESS originating from the mesentery. A few other authors have reported cases of ESS originating from extraterine organs, such as the colon [6], small bowel [7], stomach [8], round ligament [9], ovary [10], vagina [11], peritoneum [12], lung [5], and mesentery [13–16]; however, to the best of our knowledge, only four cases of ESS originating from the mesentery have been re-

Fig. 1 – (A) A 13 cm solid and cystic mass with contrast enhancement (arrow); (B) the mesenteric vein is located at the periphery of the mass (arrowhead)
The solid part of the mass (arrows) shows heterogeneous signal intensity on axial (A), coronal (B), and sagittal T2-weighted imaging (T2WI) (C), and axial T1-weighted imaging (T1WI) (D); the dorsal edge of the mass is ill-defined; diffusion is restricted in the solid part with apparent diffusion coefficient (ADC) of $1.04 \times 10^{-3}$ mm$^2$/s (E and F).

Fig. 2 – The solid part of the mass (arrows) shows heterogeneous signal intensity on axial (A), coronal (B), and sagittal T2-weighted imaging (T2WI) (C), and axial T1-weighted imaging (T1WI) (D); the dorsal edge of the mass is ill-defined; diffusion is restricted in the solid part with apparent diffusion coefficient (ADC) of $1.04 \times 10^{-3}$ mm$^2$/s (E and F).

Fig. 3 – 18F-fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) shows abnormal FDG uptake in the solid part (arrows); the maximum standardized uptake value (SUVmax) was 4.5 at 1 h after (A) and 5.9 at 2 h after isotope injection (B).

According to a study by Masand et al. [17], which summarized 63 cases of ESS with extrauterine involvement, the median age was 50 years (range, 27-87 years), and the most frequent symptoms reported were abdominal and pelvic masses, pain, genital bleeding, and gastrointestinal symptoms. Endometriosis was noted in 30/63 cases. LGESS generally has an indolent clinical course with a median overall survival of 80 months [18]. Lan et al. [19] speculated that EESS of endometrioid origin might be more prone to dissemination, as the incidence of dissemination was 76.9% in low-grade EESS arising from endometriosis, and 31% in uterine LGESS. In the present case, there was no history of endometriosis nor were there findings suggestive of endometriosis at the time of surgery.

Although it is possible that the EESS originated from subclinical endometriosis, the absence of disseminated lesions in the present case may be related to the absence of coexisting endometriosis.

Preoperative diagnosis of EESS is considered challenging, especially in the absence of uterine ESS, as in the present case, because of the rarity of the condition and the radiological similarities with other tumors, such as leiomyoma, leiomyosarcoma, and gastrointestinal stromal tumor. Radiologically, uterine LGESS forms a polypoidal endometrial mass with a well-defined or infiltrative border [20,21]. MRI typically shows heterogeneous isointensity on T1WI and heterogeneous hyperintensity on T2WI [21], but the signal intensity on T2WI may vary depending on the degenerative changes [22]. Several characteristic MRI features of LGESS have been reported in the available English literature, and the present case is the first to report all of CT, MRI, and FDG-PET/CT findings.
The large polycystic part of the tumor was a major characteristic of the present case. We speculated that the cystic components of EESS might tend to be larger than those in uterine ESS, given the lower pressure from the surrounding tissues in the uterine myometrium. However, very few studies have focused on this issue. Khan et al. [14] reported two EESS cases (the grade was low in one patient but undescribed for the other), in which CT imaging showed large tumors occupying the right lobe of the liver, and most of the tumors had large cystic components in both cases. Kim et al. [7] reviewed 16 EESS cases, including the 2 cases reported by Khan et al. [14], and 4 EESS cases contained cystic parts macroscopically, although the grade was unknown in 3 of them. In a review of low-grade EESS by Xie et al. [28], 2 out of 9 included cystic parts macroscopically; however, information about the size of the cystic components was unavailable. For uterine LGESS, although cystic change is frequent (up to 70%), cystic components tend to be small as seen in the study by Park et al. [29], in which the mean size of 10 LGESS cases including 7 cystic components was 2.8 cm (range, 1.3–4.5 cm). EESS may therefore be characterized by a tendency to have a larger cystic component compared to uterine ESS. To confirm this, further investigation with a larger number of patients is needed.

Pathological findings of low-grade EESS are similar to those of uterine LGESS [4]. Macroscopically, LGESS is circumscribed, solid, and multinodular. It is composed of monotonous cells with scant cytoplasm and minimal atypia [30]. Immunohistochemically, ESS is positive for CD10, ER, and progesterone receptor, and may also be positive for smooth muscle markers, including H-cardesmon and desmin [31]. Ki-67 index and p53 immunoreactivity were lower than those of HGESS. LGESS fre-
quently involves fusion of two zinc finger genes between chromosomes 7 and 17, JAZF1/SUZ12 and/or JAZF1/PHF1, which is useful for differentiating LGESS from HGESS [32]. These pathological features were also found in the present case, including the recombination of the JAZF1 gene seen in FISH. The management of EESS usually follows that of uterine ESS [33], where the first-line treatment is hysterectomy and adnexectomy, followed by adjuvant hormonal therapy [34]. In cases of EESS, resection of the EESS is also required. The benefits of adjuvant hormonal therapy for EESS may be limited, however, especially in cases of advanced or metastatic disease [33].

Conclusion

We have reported herein a case of low-grade EESS originating from the mesentery, without uterine ESS or evidence of endometriosis, which was formally diagnosed through FISH. CT, MRI, and FDG-PET/CT imaging showed a 13 cm mainly polycystic mass containing a contrast-enhanced solid component with restricted diffusion and mild FDG uptake. A large cystic component may be a characteristic feature of EESS, given the low pressure of the surrounding tissues, although further investigation is necessary.

Patient Consent Statement

Informed consent for patient information to be published in this article was obtained.

REFERENCES

[1] Puliyath G, Nair MK. Endometrial stromal sarcoma: a review of the literature. Indian J Med Paediatr Oncol 2012;33:1–6. doi:10.4103/0971-5851.96960.
[2] Kurman RJ, Carcangiu ML, Young RH, Simon Herrington C. 2014. WHO classification of tumours of female reproductive organs. International Agency for Research on Cancer, Lyon, France.
[3] Oliva E, Egger JF, Young RH. Primary endometrioid stromal sarcoma of the ovary: a clinicopathologic study of 27 cases with morphologic and behavioral features similar to those of uterine low-grade endometrial stromal sarcoma. Am J Surg Pathol 2014;38:305–15. doi:10.1097/PAS.0000000000000145.
[4] Wang F, Lei R, Yang H, Guo M, Tan G. Endometrial stromal sarcoma: a clinicopathological analysis of 14 cases. Int J Clin Exp Pathol 2018;11(5):2799–804.
[5] Alessandrini R, Sopracordevole F, Bertola G, Scalone S, Urbani M, Miolo G, et al. Primary extragenital endometrial stromal sarcoma of the lung: first reported case and review of literature. Diagn Pathol 2017;12:36. doi:10.1186/s13000-017-0627-2.
[6] Son HJ, Kim JH, Kang DW, Lee HK, Park MJ, Lee SY. Primary extraterine endometrial stromal sarcoma in the sigmoid colon. Ann Coloproctol 2015;31:68–73. doi:10.3393/ac.2015.31.2.68.
[7] Kim L, Choi SJ, Park IS, Han JY, Kim JM, Chu YC, et al. Endometrial stromal sarcoma of the small bowel: a case report and review of literature. Ann Diagn Pathol 2008;12:128–33. doi:10.1016/j.anndiagpath.2006.03.020.
[8] Jin M, Reynolds JP, Odronic SI, Wakely PE. Primary gastric extra-uterine endometrial stromal sarcoma. Ann Diagn Pathol 2014;18:187–90. doi:10.1016/j.anndiagpath.2014.02.001.
[9] Migliani U, Laul P, Bindal N, Chhibber P, Saxena P. Extraterine endometrial stromal sarcoma: a rare entity. Indian J Gynecol Oncol 2019;17:38. doi:10.407/ijgyno.2007.01.031.
[10] Efared B, Sidibé IS, Erregud F, Hammas N, Chibani L, el Fatemi H. Extra-uterine low grade endometrioid stromal sarcoma arising from ovarian endometriosis: a case report and review of the literature. Gynecol Oncol Res Pract 2019;6(2). doi:10.1186/s40663-019-0067-7.
[11] Liu Z, Ding J, Li X, Yu K. Endometrial stromal sarcoma arising in vagina. Int J Clin Exp Pathol 2013;6:2997–3002.
[12] Clair K, Wolford J, Veran-Taguibo S, Kim G, Eskander RN. Primary low-grade endometrial stromal sarcoma of the Omentum. Gynecol Oncol Rep 2017;21:119–21. doi:10.1016/j.gore.2017.08.002.
[13] Welfel J, Gottwald L, Kowalczyk-Amiko K, Szwalski J, Lech W, Suzin J. Low-grade endometrial stromal sarcoma firstly localized in colonic mesentery. Ginekol Pol 2004;75:150–2.
[14] Khan AW, Craig M, Jarmulowicz M, Davidson BR. Liver tumours due to endometriosis and endometrial stromal sarcoma. HPB 2002;4(1):43–6. doi:10.1036/s16518200750000735.
[15] Schoolmeester JK, Scalllas A, Greipp PT, Hodge JC, Cin PD, Keeney GL, et al. Analysis of MDM2 amplification in 43 endometrial stromal tumors: a potential diagnostic pitfall. Int J Gynecol Pathol 2015;34:576–83. doi:10.1097/pgp.0000000000000187.
[16] Verma A, Menon S, Rekhi B, Pai T, Maheshwari A, Ghosh J, et al. Utility of YWHAE fluorescent in-situ hybridisation in mesenchymal tumors of uterus—an initial experience from tertiary oncology centre in India. Indian J Cancer 2019;56(4):335–40. doi:10.4103/ijc.jc.722_18.
[17] Masand RP, Euscher ED, Deavers MT, Malpica A. Endometrioid stromal sarcoma: a clinicopathologic study of 63 cases. Am J Surg Pathol 2013;37:1635–47. doi:10.1097/PAS.0000000000000838.
[18] Leath CA, Huh WK, Hyde J, Cohn DE, Resnick KE, Taylor NP, et al. A multi-institutional review of outcomes of endometrial stromal sarcoma. Gynecol Oncol 2007;105:630–4. doi:10.1016/j.ygyno.2007.01.031.
[19] Lan C, Huang X, Lin S, Cai M, Liu J. Endometrial stromal sarcoma arising from endometriosis: a clinicopathological study and literature review. Gynecol Obstet Invest 2012;74:288–97. doi:10.1159/000341706.
[20] Huang YL, Ueng SH, Chen K, Huang YT, Lu HY, Ng KK, et al. Utility of diffusion-weighted and contrast enhanced magnetic resonance imaging in diagnosing and differentiating between high- and low-grade uterine endometrial stromal sarcoma. Cancer Imat 2019;63(3):19. doi:10.1002/cam4.20472.
[21] Chattra PA, Gyanchandani M, Goolahally LN, Itagi RM, Kalenahalli KV. Endometrial stromal sarcoma: an aggressive uterine malignancy. J Radiol Case Rep 2016;10(9):35–43. doi:10.3941/jrcr.v10i9.2770.
[22] Li HM, Liu J, Qiang JW, Gu WY, Zhang GF, Ma FH. Endometrial stromal sarcoma of the uterus magnetic resonance imaging findings including apparent diffusion coefficient value and its correlation with Ki-67 expression. Int J Gynecol Cancer 2017;27(9):1877–87. doi:10.1097/IGC.0000000000001114.
[23] Koyama T, Togashi K, Konishi I, Kobayashi H, Ueda H, Kataoka ML, et al. MR imaging of endometrial stromal sarcoma: correlation with pathologic findings. Am J Roentgenol 1999;173:767–72. doi:10.2214/sjr.173.3.10470920.
[24] Santos P, Cunha TM. Uterine sarcomas: clinical presentation and MRI features. Diagn Interv Radiol 2015;21:4–9. doi:10.5152/dir.2014.14053.

[25] Huang YT, Huang YL, Ng KK, Lin G. Current status of magnetic resonance imaging in patients with malignant uterine neoplasms: a review. Korean J Radiol 2019;20(1):18–33. doi:10.3348/kjr.2018.0090.

[26] Yamamoto M, Tsujikawa T, Yamada S, Kurokawa T, Shinagawa A, Chino Y, et al. 18F-FDG/18F-FES standardized uptake value ratio determined using PET predicts prognosis in uterine sarcoma. Oncotarget 2017;8:22581–9. doi:10.18632/oncotarget.15127.

[27] Fujiishi K, Nagata S, Kano R, Kubo C, Shirayanagi M, Ozaki M, et al. JAZF1–SUZ12 endometrial stromal sarcoma forming subserosal masses with extraordinary uptake of fluorodeoxyglucose on positron emission tomography: a case report. Diagn Pathol 2019;14:110. doi:10.1186/s13000-019-0897-y.

[28] Xie W, Bi X, Cao D, Yang J, Shen K, You Y. Primary endometrioid stromal sarcomas of the ovary: a clinicopathological study of 14 cases with a review of the literature. Oncotarget 2017;8:63345–52. doi:10.18632/oncotarget.18805.

[29] Park GE, Rha SE, Oh SN, Lee A, Lee KH, Kim MR. Ultrasonographic findings of low-grade endometrial stromal sarcoma of the uterus with a focus on cystic degeneration. Ultrason 2016;35:124–30. doi:10.14366/usg.15045.

[30] Lipsch F, Andrieu PIC, Wernicke A, Patrono MG, Napoli MN, Beatriz Chacon CR, et al. Extra-uterine endometrial stromal sarcoma arising from deep infiltrating endometriosis. Clin Imag 2020;67:250–4. doi:10.1016/j.clinimag.2020.08.015.

[31] Sato S, Ojima Y, Kanda M, Kizaki T, Ohara N. Endometrial stromal sarcoma arising from endometrial polyp: a case report. Kobe J Med Sci 2018;64(2):E36–42.

[32] Hodge JC, Bedroske PP, Pearce KE, Sukov WR. Molecular cytogenetic analysis of JAZF1, PHF1, and YWHAE in endometrial stromal tumors discovery of genetic complexity by fluorescence in situ hybridization. J Mol Diagn 2016;18:516–26. doi:10.1016/j.jmoldx.2016.02.001.

[33] Mercier NB, Roberts LF, Azordegan N, Altman AD. Extra-uterine endometrial stromal sarcoma of the left adnexa and distal ureter: a case report. Gynecol Oncol Rep 2021;36:100702. doi:10.1016/j.gorep.2021.100702.

[34] Thiel FC, Halmen S. Low-grade endometrial stromal sarcoma—a review. Oncol Res Treat 2018;41:687–92. doi:10.1159/000494225.